Brief: Galmed Updates Business And Clinical Development Strategy To Better Leverage Aramchol's Anti-Fibrotic Effects

Eocene

17/05/2022 12:43

Galmed Pharmaceuticals Ltd  GLMD.O :
    * GALMED UPDATES BUSINESS AND CLINICAL DEVELOPMENT STRATEGY
TO
BETTER LEVERAGE ARAMCHOL'S ANTI-FIBROTIC EFFECTS
    * GALMED PHARMACEUTICALS LTD - RECENT DATA REINFORCE
ANTI-FIBROTIC
ACTIVITY OF ARAMCHOL PREVIOUSLY OBSERVED IN A WIDE RANGE OF
PRE-CLINICAL MODELS
    * GALMED-OPEN-LABEL PART OF ARMOR STUDY MET OBJECTIVES
DEMONSTRATING CONSISTENT ANTI-FIBROTIC EFFECTS AT 48 WEEKS IN
NASH PATIENTS & WILL BE DISCONTINUED
    * GALMED - INITIATING PLAN INCLUDING A COST REDUCTION EFFORT
WHICH
WILL ENABLE CO TO DEVELOP ARAMCHOL FOR NEW FIBROTIC INDICATIONS
WITH HIGH UNMET NEED

Source text for Eikon:  ID:nPnbj6NZBa 
Further company coverage:  GLMD.O